Statistics
Last Updated
Jun 9, 2026
Table of contents
The pharmaceutical industry is one of the largest on earth, worth roughly $1.6 trillion a year, and right now a single category is rewriting its rankings. Diabetes and obesity drugs have pushed one company to a trillion-dollar valuation and now account for several of the world's best-selling medicines. Here is the industry by the numbers, updated for 2026.
The headline numbers
Pharma in four figures.
Market size
A $1.6 trillion industry, still growing.
The global market reached about $1.6 trillion in 2024 and is projected to approach $2.4 trillion by 2029, growing 5 to 8 percent a year. Growth is slowing in percentage terms as blockbusters lose patent protection, but the dollars added over the next five years exceed the last five.
Global pharmaceutical market size in trillions of US dollars. 2024 actual and 2029 projection per IQVIA. Invoice spending, excluding one-time COVID-19 vaccine surges.
The biggest players
Largest pharma companies by revenue.
Ranked by 2024 pharmaceutical-segment revenue. The order shifts depending on how each company's non-pharma businesses are counted, and Roche and Novartis sit just behind this group.
2024 pharmaceutical revenue, in billions of US dollars. Sources: company filings and industry reporting.
The trend behind the numbers
The metabolic boom is rewriting the rankings.
The clearest force in pharma today is the rise of GLP-1 medicines for diabetes and weight loss. In late 2025 Eli Lilly became the first pharmaceutical company in history to reach a $1 trillion market capitalization, on the strength of its GLP-1 drugs. Its market value is now more than double that of its nearest rival. Four of 2025's ten best-selling drugs are GLP-1s, and Lilly's tirzepatide plus Novo Nordisk's semaglutide were on track for more than $70 billion in combined sales in 2025 alone.
Market capitalization, late 2025. Eli Lilly became the first pharmaceutical company to cross $1 trillion, worth more than double its nearest rival. Market caps fluctuate daily.
Of the ten best-selling drugs worldwide in 2025, four are GLP-1 medicines for diabetes and weight loss.
What it costs
US drug spending, four decades.
US prescription drug spending reached $467 billion in 2024, up 7.9 percent from the year before. The long arc is steep: about $30 billion in 1980, $335 billion in 2018, and $467 billion today.
US prescription drug spending, in billions of US dollars. Source: CMS National Health Expenditure data.
In context
Drugs are a smaller slice than you think.
Prescription drugs dominate the headlines, but they are under a tenth of US health spending. Of the $5.3 trillion the country spent on healthcare in 2024, hospitals and physician services took more than half, while retail prescription drugs were roughly 9 percent.
Share of $5.3 trillion in total US health spending, 2024. Source: CMS National Health Expenditure data.
The strain
Affordability is still the sore point.
Generics blunt some of the pain, filling about 90 percent of US prescriptions at a fraction of brand-name prices, and Medicare drug-price negotiation under the Inflation Reduction Act is expected to slow per-person spending growth over the coming decade. Source: KFF.
The workforce
Pharmacists, by the numbers.
Pharmacists remain one of the better-paid healthcare professions, though the work is shifting from shrinking retail counters toward hospital and clinical settings.
| Metric | Figure (2024) |
|---|---|
| Pharmacists employed in the US | 335,100 |
| Median annual wage | $137,480 |
| Projected job growth, 2024 to 2034 | 5% (faster than average) |
| Annual job openings, projected | ~14,200 |
| Highest-paying state | California |
| Top-paying metro area | San Jose, CA (~$187,480 mean) |
| Share who are women | ~57% |
Source: US Bureau of Labor Statistics, Occupational Outlook Handbook and May 2024 wage data.
What comes next
The outlook to 2030.
Three forces will shape the rest of the decade. The metabolic wave keeps building as GLP-1s expand into new uses with a deep pipeline behind them. A wall of patent expirations is coming for some of the industry's biggest oncology and immunology sellers, opening the door to biosimilars and reshuffling the rankings. And pricing pressure from the Inflation Reduction Act will keep net growth below what gross sales suggest. Underneath all of it is a steady shift toward biologics and precision medicine, treatments guided by an individual's own biology rather than the population average.
Sources: IQVIA Institute (Global Use of Medicines Outlook through 2029); US Centers for Medicare and Medicaid Services (National Health Expenditure data, 2024); US Bureau of Labor Statistics (Occupational Outlook Handbook, May 2024); KFF; and company financial filings and reporting. Figures are current as of 2026 and rounded. Market-size estimates vary by source and methodology.
Lifelong Optimization
Not your average
Checkup
Every life stage brings new biological demands. Tracking the right metrics at the right time helps you adapt, optimize performance, and extend both lifespan and healthspan.
Traditional
Manual Data Processing
Guesswork Trend Detection
Slow Campaign Setup
Multiple Tools, Multiple Logins
Reactive Decision-Making
Manual Reporting
Delayed Results
High Error Risk
Automated Data Sync
Real-Time Trend Insights
Instant AI Optimization
All-in-One Platform
Proactive AI-Driven Strategies
Auto-Generated Reports
Instant Performance Updates
AI Precision
Frequently Asked Questions
Clarity before
you commit
Answers on setup, scale, and support to remove blockers.
